Follow the WDRB Newsroom, Reporters and Anchors.More >>
Tweets from the WDRB Newsroom, Reporters and Anchors.More >>
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Endocellutions, Inc.
BOSTON, Feb. 25, 2014 /PRNewswire/ -- Endocellutions, Inc. has announced that it is appointing Andrew McGillicuddy, a seasoned financial executive with a strong healthcare background, as its Chief Executive Officer.
"We are thrilled that Andrew is joining Endocellutions at what is a very exciting time for our company," said Jeff Chabot, PhD., a founding member of Endocellutions. "Andrew's proven record of structuring creative financing, licensing, and distribution deals will be a great addition to our team's capability. His financial and strategic skill-sets are exactly what we are looking for as we begin to explore the market for our exciting technologies. "
"I am honored to be joining the Endocellutions team at such a critical time in the company's development. The opportunity to join with such a talented group of engineers and scientists doing very important work in a rapidly emerging field is truly energizing," McGillicuddy said.
Prior to joining Endocellutions, McGillicuddy held various financial management positions at Deloitte & Touche, Primark, and Harvest Technologies. Andrew graduated from Bates College and holds the credentials of CPA and CFA.
About Endocellutions Endocellutions is a development-stage medical device company founded to create simple, cost effective, safe technologies that enable clinicians to practice regenerative medicine using autologous, minimally manipulated tissues at point of care. Its mission is to work with clinicians to facilitate repair of damaged tissue and improve the healing process.